Background:
Serum potassium is a known prognostic marker in patients with heart failure (HF) and chronic kidney disease (CKD), with both hypo- and hyperkalemia associated with adverse outcomes. The POTCAST trial demonstrated that targeting a potassium range of 4.5-5.0 mmol/L may be optimal in patients at high risk f...
Henri Lu, B. Claggett, G. Filippatos et al.· Circulation· 0 citations
BACKGROUND
The HFpEF-ABA score is a simple diagnostic tool developed to estimate the probability of heart failure with preserved ejection fraction (HFpEF) using age, body mass index, and history of atrial fibrillation.
OBJECTIVES
This study aims to evaluate the HFpEF-ABA score in patients with confirmed heart failure...
R. Ono, K. Docherty, A. Henderson et al.· JACC. Heart failure· 0 citations
BACKGROUND
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) face high but modifiable risks of incident heart failure (HF). We aimed to ascertain whether the HFpEF-ABA score, a simple 3-variable tool to facilitate timely diagnosis of HFpEF, is associated with adverse cardiovascular (CV) outcomes in p...
R. Inciardi, J. Ostrominski, B. Claggett et al.· Journal of Cardiac Failure· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.